Medical industry veteran Nicolas Barthelemy brings extensive global leadership experience and a track record of success in the life sciences and biopharmaceutical industries to bioTheranostics. Previously, he held a number of executive-level positions at Life Technologies/Invitrogen, including Chief Commercial Officer and President of the Cell Systems Division. He also held senior-level positions at Biogen Idec, and he began his career at Merck & Co. Nicolas has a proven ability to build high-performance teams that are able to achieve rapid and sustained improvements in business results. He serves on the boards of several private and public life sciences companies. Barthelemy earned a Master of Science in chemical engineering from the University of California, Berkeley, and a graduate degree in chemistry from the Ecole Supérieure de Physique et Chimie Industrielles in Paris.
Dr. Sue Beruti has more than seven years of industry experience in diagnostic and therapeutic oncology, pathology, biopharma, and companion diagnostics. Previously, Dr. Beruti served as Director of Pathology and Medical Affairs at Genoptix (a Novartis oncology company), where she led the BioPharma and Medical Affairs divisions, a role which included providing oversight of multiple clinical trials in collaboration with major academic institutions and cancer centers. She is board certified in anatomic pathology, clinical pathology, and hematopathology. Beruti received a bachelor’s degree in cell and molecular biology from the University of Michigan, and a medical degree and master’s degree in health administration from the Ohio State University College of Medicine and Public Health.
Dr. Ramesh Hariharan’s career of 16 years spans a wide range of subspecialties, including basic research, strategic management consulting, and marketing. At GE’s Basic Research Center, he was nominated Best Young Scientist for his innovations, which included a new molecule that allowed for higher data densities in rewritable DVDs and a novel process for agglomerating nanoparticles. At McKinsey, he served biotech, pharma, medical device, diagnostic, and private equity leaders in the U.S., Germany, and the U.K., tackling a wide range of business issues such as product launches, market expansion, life cycle strategies, and business turnarounds. Dr. Hariharan then held marketing leadership positions in Oncology, Women’s Health, Pain, and Vaccines at Novartis and Abbott/AbbVie. He received a bachelor’s degree in chemical engineering from IIT Bombay, a Ph.D. in chemical engineering from Princeton University, and an MBA from MIT Sloan School of Management.
Macey Johnson is a 26-year veteran of the biotechnology and molecular genomics industries, with a specific focus in oncology, having launched some of the most successful therapeutic and diagnostic products in the oncology space. Past employers include Marion Labs, Genentech, and Genomic Health, where he was responsible for leading Managed Care Marketing and Reimbursement Strategy. Macey received his bachelor’s degree in history from the University of South Alabama and a master’s degree in strategic planning from the University of Alabama.
Matt Sargent has more than 16 years of life science experience, with a strong focus in molecular oncology diagnostics. He most recently was Vice President of Oncology Sales for Caris Life Sciences, where he built and trained the oncology sales team, resulting in significant sales growth and market penetration of their molecular profiling and NGS product line. He has also held senior sales leadership positions at MedTrust Online and Exiqon Diagnostics. Matt received a bachelor’s degree in anatomy and animal physiology from Cornell University, a master’s degree in cancer physiology from the State University of New York at Buffalo, and a master’s degree in business administration from Pepperdine University.
Dr. Catherine Schnabel has over 15 years of experience as an industry scientist across pharmaceutical, clinical and diagnostics research, including positions with Genentech, Genoptix, and Amylin Pharmaceuticals. Joining bioTheranostics in 2009, she has led the translational science and strategic programs for clinical development of proprietary molecular diagnostics in oncology and genomic medicine. Schnabel received her Ph.D. in molecular and cellular biology at the Center for Advanced Biotechnology and Medicine, and was a postdoctoral fellow of the NIH and the Leukemia and Lymphoma Society at Stanford University. Schnabel is an industry leader in the development of evidence-based diagnostics and in building clinical value for molecular tests. She is a named co-inventor on several patents and has authored numerous publications. As Chief Scientific Officer, Dr. Schnabel provides scientific leadership and continued oversight of clinical development, medical strategy, and regulatory plans for bioTheranostics’ products.
Dr. Jennifer Skeen brings more than 10 years of clinical laboratory operations management experience to bioTheranostics, including positions at Pathway Genomics, Asuragen, and Alverno Clinical Laboratories. Dr. Skeen has served in development, operational performance, quality assurance, and scientific leadership capacities, successfully launching oncology diagnostics and leading teams in strategic development and commercialization. At Asuragen, she led the Genomic Services and CLIA laboratories in developing companion diagnostic tests and commercializing proprietary test offerings for oncology and genetic disorders, as well as ensuring premier quality and compliance with national and state accreditation requirements. Skeen holds a doctorate in molecular genetics and biochemistry from the University of Illinois, Chicago, and a bachelor’s degree in biology from the University of Illinois, Urbana-Champaign.
Gail Sloan has over 20 years of financial experience at publicly traded (NASDAQ) companies in the life sciences industry, as well as 8 years with a Big 4 accounting firm. Prior to joining bioTheranostics, Sloan held the Chief Financial Officer and VP Finance positions at La Jolla Pharmaceutical Co. (LJPC), a publicly traded biopharmaceutical company. During her 16-year tenure at LJPC, she played a key role in raising more than $330 million through multiple private placements and public offerings and was responsible for all finance activities, including SEC reporting and compliance with Sarbanes-Oxley Act requirements. Previously, Sloan was Assistant Controller at Affymax Research Institute (AFFY), a publicly traded drug discovery technology company, prior to its acquisition by Glaxo Wellcome in 1995. While at AFFY, Sloan helped lead the spin-out of Affymetrix Inc. (AFFX), a manufacturer of DNA microarrays. Sloan started her finance career at the public accounting firm of Ernst & Young, LLP, where she attained the position of Audit Manager. Sloan is a certified public accountant with the State of California and earned her B.S. in business from California Polytechnic State University, San Luis Obispo.
Board of Directors
Brian Armstrong is the Chief Financial Officer for bioMérieux Inc. Based in Durham, North Carolina, he is responsible for all financial aspects of the bioMérieux-U.S. operations. Armstrong has been with bioMérieux for 17 years. Prior to joining bioMérieux, he was Audit Senior Manager with Ernst & Young. He is a CPA and member of AICPA.
Richard Ding has progressive leadership experience in the biopharmaceutical and diagnostic industry. He was a member of the research team at Myriad Genetics that discovered BRCA and developed one of the first and most prominent genetic tests. Ding subsequently joined Eli Lilly, where he assumed various strategy and business development positions. In 2006, he joined bioMérieux as Vice President of Strategy and Business Development. He was CEO of bioTheranostics from 2008 – 2014. In 2014, Ding became Corporate Vice President of the Asia-Pacific Region at bioMérieux. He has served on the board of directors of several life science and diagnostic companies. Ding holds an MBA from the University of Utah and received his undergraduate education at Fudan University, China.
Brad Smith is a former Vice Chairman of LabCorp. He has extensive executive experience in operations and legal and corporate affairs within the diagnostics and clinical laboratory industry. His previous positions include Assistant Vice President of Law and General Counsel with Roche Biomedical Laboratories.
François Valencony began his career at Schneider Electric in Chicago, where he participated in several acquisitions and growth plans for the divisions of North America and South America until 2000. He then actively participated in the construction of a start-up in IT, based in London, which was acquired by the Descartes Group. Valencony joined the Institut Mérieux in 2003 with a strategic involvement in the fields of diagnostics and biotechnology, driving acquisitions and the establishment of international licensing agreements. His operational responsibilities included the establishment of the first bioMérieux research center in China and management of five immunotherapy development programs. Valencony is currently CEO of Mérieux Développement and president of the U.S. subsidiary MxD North America. He graduated from HEC Paris and earned a CEMS master’s degree in Cologne, Germany.
Lale White is founder and CEO of XIFIN, Inc. XIFIN is the innovator and provider of a new accounts receivable and financial management application for the healthcare industry. White is a nationally recognized expert in the field of medical financial management and regulatory compliance. She lectures and consults extensively on these topics to major laboratories and laboratory associations throughout the U.S. She has over 20 years of successful executive leadership in financial management, information systems development, and medical billing with several of the largest independent clinical reference laboratories, where she held senior management positions. Prior to founding XIFIN, White was Vice President of Finance at Laboratory Corporation of America. She was also a principal contributor in working with HCFA and the U.S. Office of the Inspector General to develop the current OIG Model Compliance Program. White holds an MBA in finance from Florida International University.